Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) (PILLAR)

Astellas

Status and phase: Completed; Phase 4

Conditions: Overactive Bladder (OAB)

Treatments: Drug: Placebo; Drug: Mirabegron

Study type: Interventional

Funder types: Industry

Identifiers

NCT02216214

178-MA-1005

Details and patient eligibility

About

The purpose of this study was to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.

Enrollment: 888 patients

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria assessed at Visit 1 (Screening):

• Subject is willing and able to complete the micturition diary and questionnaires correctly.
• Subject has symptoms of wet overactive bladder (OAB) (urinary frequency and urgency with incontinence) for greater than or equal to 3 months prior to Screening.
• Subject agrees not to participate in another interventional study from the time of screening until the final study visit.

Inclusion Criteria assessed after placebo run-in period at Visit 3 (Baseline):

• Subject continues to meet all inclusion criteria of Visit 1.
• Subjects must experience at least one incontinence episode in the placebo run-in period based on the 3-day micturition diary.
• Subject must experience at least 3 episodes of urgency (grade 3 or 4) based on the 3-day micturition diary.
• Subject must experience an average of greater than or equal to 8 micturitions/day based on the 3-day micturition diary.

Exclusion Criteria assessed at Visit 1 (Screening):

• Subject has ongoing symptoms suggestive of bladder outlet obstruction (BOO) or history of BOO that is currently not well controlled.
• Subject has Post-Void Residual Volume (PVR) greater than 150 mL.
• Subject has neurogenic bladder or neurological dysfunction or injury which could affect the lower urinary tract or nerve supply.
• Subject has significant stress incontinence or mixed stress/urgency incontinence where stress is the predominant factor as determined by the Investigator (for female subjects confirmed by a cough provocation test). Subjects with a history of stress incontinence that is currently treated (e.g. remote history of surgery for stress incontinence) may be included as long as they pass cough provocation test.
• Subject has an indwelling catheter or practices intermittent self-catheterization.
• Subject has evidence of Urinary Tract Infection (UTI). Urine culture and sensitivity will be performed for positive leukocytes, or nitrites, or turbidity, or at the investigator's discretion and will be confirmed with a culture greater than 100,000 cfu/mL. If a subject has a UTI at Screening (Visit 1), the subject can be rescreened after successful treatment of the UTI (confirmed by a laboratory result of negative urine culture).
• Subject has a chronic inflammatory condition such as interstitial cystitis, bladder stones, previous pelvic radiation therapy, or previous or current malignant disease of the pelvic organs (i.e., within the confines of the pelvis including the bladder and rectum in both sexes and the uterus, ovaries, and fallopian tubes in females; organs of the lower gastrointestinal tract are not necessarily considered pelvic organs as the distal ascending colon, the full transverse colon and proximal portion of the descending colon are in the abdomen).
• Subject resides in a nursing home.
• Subject is likely to enter a hospital or nursing home due to medical instability within the next 6 months in the opinion of the Investigator.
• Subject has received intravesical injection in the past 12 months with botulinum toxin, resiniferatoxin, or capsaicin.
• Subject has received electro-stimulation therapy for OAB (e.g. sacral nerve stimulation or Percutaneous Tibial Nerve Stimulation [PTNS]).
• Subject began or has changed a bladder training program or pelvic floor exercises less than 30 days prior to Screening.
• Subject has moderate or severe hepatic impairment defined as Child-Pugh Class B or C.
• Subject has severe renal impairment defined as estimated creatinine clearance less than 29 mL/min determined by Estimated Glomerular Filtration Rate (eGFR, Cockroft-Gault, or MDRD formulae). A subject with end stage renal disease or undergoing dialysis is also not a candidate for the study.
• Subject has severe uncontrolled hypertension, which is defined as a sitting systolic blood pressure greater than or equal to 180 mmHg and/or diastolic blood pressure greater than or equal to 110 mmHg.
• Subject has evidence of QT prolongation on electrocardiogram (ECG) defined as QTc greater than 450 msec for males, QTc greater than 470 msec for females or a known history of QT prolongation.
• Subject has a clinically significant ECG abnormality, as determined by the Investigator.
• Subject has aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 2x upper limit of normal (ULN), or γ-GT greater than 3x ULN and considered clinically significant by the Investigator.
• Subject has a hypersensitivity to any components of mirabegron, other β-AR agonists, or any of the inactive ingredients.
• Subject has any clinically significant condition, which in the opinion of the Investigator makes the subject unsuitable for study participation.
• Subject has been treated with an experimental device within 28 days or received an investigational agent within 28 days or 5 half-lives, whichever is longer, prior to Screening.
• Subject has a concurrent malignancy or history of any malignancy (within the past 5 years), except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully.
• Subject with current history of alcohol and/or drug abuse.
• Subject is using prohibited medications which cannot be stopped safely during the period.
• Subject has stopped, started or changed the dose of a restricted medication within the last 30 days prior to Screening.
• Subject is involved in the conduct of the study as an employee of the Astellas group, third party associated with the study, or the study site team.
• Subject has previously received mirabegron.

Exclusion Criteria assessed after placebo run-in period at Visit 3 (Baseline):

• Subject fulfills any exclusion criteria of Visit 1 (subject does not need to repeat screening assessments [PVR, cough provocation test, chemistry/hematology/urinalysis]).
• Subject was non-compliant during 2-week placebo run-in period, defined as taking less than 80% or greater than 120% of study medication.
• Subject has any systolic blood pressure measurement > 180 mmHg or diastolic blood pressure measurement > 110 in the 3-day diary or during the baseline visit.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

888 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Participants received placebo to match mirabegron at an initial dose of 25 mg and may have been increased to 50 mg of matching placebo based on individual participant efficacy, tolerability and investigator discretion. Once a participant had increased dose, they remained on that dose for the remainder of the study unless there were safety reasons that required discontinuation of study drug.

Treatment:

Drug: Placebo

Mirabegron

Experimental group

Description:

Participants received mirabegron at an initial dose of 25 mg and may have been increased to 50 mg mirabegron after 4 weeks or 8 weeks based on individual participant efficacy, tolerability and investigator discretion. Once a participant had increased dose, they remained on that dose for the remainder of the study unless there were safety reasons that required discontinuation of study drug.

Treatment:

Drug: Mirabegron